HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hawkridge, A. M. Articles by Burnett, J. C. Search for Related Content PubMed PubMed Citation Articles by Hawkridge, A. M. Articles by Burnett, J. C., Jr.

Effect of Plasma Protein Depletion on BNP-32 Recovery

¹ North Carolina State University, W.M. Keck FT-ICR Mass Spectrometry Laboratory, Department of Chemistry, Raleigh, NC
² Mayo Clinic College of Medicine, Department of Internal Medicine, Division of Cardiovascular Diseases, Rochester, MN

^aAddress correspondence to this author at: North Carolina State University, W. M. Keck FT-ICR Mass Spectrometry Laboratory, 2620 Yarbrough Drive, Box 8204, Raleigh, NC 27695, Fax 919.513.7993, e-mail adam_hawkridge@ncsu.edu

The first 20% of the full text of this article appears below.

To the Editor:

Depletion of abundant proteins from plasma and serum is an important initial step in many biomarker discovery platforms(1). Decreasing the concentrations of highly abundant proteins (e.g., albumin, IgG, and antitrypsin) facilitates the use of contemporary proteomics technologies, such as gel electrophoresis and mass spectrometry, for detection and identification of low-abundant proteins. Furthermore, decreasing abundant protein concentrations may also improve immunoprecipitation recovery efficiencies for targeted low-abundant species by decreasing nonspecific binding (i.e., shielding the antigen-binding domain) to the antibody and/or solid supports. A notable pitfall to depletion strategies is the potential for unintentionally removing low-abundant plasma or serum proteins. These low-abundant species may be bound specifically or nonspecifically to the depletion ligand, depletion target protein (e.g., carrier proteins), or the solid support(s). Thus, it is important to critically evaluate the effectiveness of abundant plasma protein depletion for enhancing the study of low-abundant protein biomarker(s).

We have been actively developing a targeted biomarker discovery platform for characterizing the circulating forms of B-type natriuretic peptide (BNP) that includes protein . . . [Full Text of this Article]